Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC1911 Egfr T790m Inhibitor 6a
Novel third-generation EGFR tyrosine kinase inhibitor, targeting EGFR T790M mutation in advanced non-small cell lung cancer
More description
DCC1910 Efrotomycin
Antibiotic, inhibiting bacterial protein synthesis
More description
DCC1909 Efrapeptin F
Natural alpha-aminobutyric acid-rich secondary metabolite of fungi, strongly inhibiting the BBMV V-ATPase, acting as a mitochondrial complex V inhibitor, showing antitumor activity in vivo
More description
DCC1908 Efonidipine
Calcium channel blocker, blocking both T-type and L-type calcium channels
More description
DCC1907 Efatutazone
Potent agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity
More description
DCC1906 Eef2k-in-21i
Novel eEF2K inhibitor, inducing significant apoptosis through classical apoptotic pathways
More description
DCC1905 Edoxaban Isomer
An impurity of Edoxaban, a novel inhibitor of factor Xa
More description
DCC1904 Ecraprost
Lipo-pro-prostaglandin E1, preventing hearing disturbance and equilibrium dysfunction due to inner ear microcirculatory disorders
More description
DCC1903 Echinoside A
Novel marine-derived anticancer saponin, targeting topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle
More description
DCC1902 Ecdsbb-in-9
Novel specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria
More description
DCC1901 Ecdsbb-in-12
Novel potent specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme
More description
DCC1900 Ebv Activator C60
Novel EBV activator, well-performing EBV lytic cycle inducer
More description
DCC1899 Ebselen Oxide
Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9, inhibiting Pseudomonas aeruginosa alginate synthesis
More description
DCC1898 Ebov-in-c31
Novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties
More description
DCC1897 Ebopiprant
Novel Oral and Selective Prostaglandin F 2α (PGF 2α ) Receptor Antagonist
More description
DCC1896 Ebmi-13b
Highly potent and selective activator of isozymes CA-VA and CA-VII
More description
DCC1895 Ebi-13a
Highly potent and selective activator of isozymes CA-VA and CA-VII
More description
DCC1894 Ea-b3a
Novel degrader of GST-α and GST-α-EGFP fusion proteins as well as endogenous GST-π in cells and lysates
More description
DCC1893 E-5842 Citrate
Sigma1 receptor ligand and potential atypical antipsychotic
More description
DCC1892 E3-ligase Degrader 10
Novel XIAP BIR2 domain-binding degrader of E3 ubiquitin ligases
More description
DCC1891 E235-1756
Potent Activator of P53-Independent Cellular Senescence
More description
DCC1890 e2012-bpyne
γ-Secretase modulator (GSM) photoaffinity probe, revealing distinct allosteric binding sites on presenilin
More description
DCC1889 E09241
Novel OPG/RANKL upregulator, increasing OPG expression without affecting RANKL expression, promoting osteoblast differentiation while inhibiting osteoclast differentiation, regulating OPG expression through canonical Wnt/β-catenin signaling
More description
DCC1888 Dy428174
Novel potent Inhibitor of PI3Kalpha
More description
DCC1887 Dy3002
Novel Selective and Potent EGFR Inhibitor, Overcoming T790M-Mediated Resistance in Non-Small Cell Lung Cancer
More description
DCC1886 Dx-52-1
Antitumor antibiotic
More description
DCC1885 Dx2-hsp70 Inhibitor-1
Novel allosteric inhibitor of the tumor-promoting interaction between the oncogenic factor AIMP2-DX2 and HSP70
More description
DCC1884 Dwn-723-23
Novel Hsp70 agonist, showing no cellular toxicity and induced cellular stress response pathways
More description
DCC1883 Dw-1350
Novel and potent leukotriene B(4) receptor antagonist
More description
DCC1882 Dw10075
Novel potent and highly selective inhibitor of VEGFR, exhibiting antitumor activities both in vitro and in vivo.
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X